Overview and Scope
CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, and the Cas (CRISPR-associated) gene, particularly Cas9, constitute a powerful gene-editing technology. This system enables precise modifications to DNA sequences, revolutionizing genetic research, biotechnology, and potential medical applications.
Sizing and Forecast
The crispr and cas gene market size has grown exponentially in recent years. It will grow from $3.28 billion in 2023 to $3.97 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increased consumer awareness, shift in consumer values, rise in celebrity endorsements, rise of veganism, increased social media influence.
The crispr and cas gene market size is expected to see exponential growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to global expansion of bans, rising conscious consumerism, emergence of new brands, consumer education initiatives, beauty inclusivity. Major trends in the forecast period include technology advancements, product innovations, circular beauty economy, men's grooming segment, social justice and ethical sourcing.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report
Segmentation & Regional Insights
The crispr and cas gene market covered in this report is segmented –
1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types
2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis
3) By Application: Clinical, Financial, Operational And Administrative
4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)
North America was the largest region in the CRISPR and Cas gene market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr and cas gene market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=13632&type=smp
Major Driver Impacting Market Growth
A growing focus on personalized therapy is expected to propel the growth of the CRISPR and Cas gene markets going forward. Personalized therapy refers to a medical model that uses an individual's genetic profile to guide decisions made concerning the diagnosis, treatment, and prevention of disease. CRISPR and the Cas gene, particularly Cas9, are used in personalized medicine, enabling precise modifications to an individual's genetic material and holding promise for breakthroughs in developing tailored therapies for genetic disorders, cancer, and various medical conditions. For instance, in January 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the rising demand for personalized therapy will drive the growth of the CRISPR and Cas gene markets.
Key Industry Players
Major companies operating in the crispr and cas gene market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc., Danaher Corporation, Quest Diagnostics, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, Myriad Genetics Inc., GenScript, Takara Bio Inc., 23andMe Inc., Merck KGaA, Color Genomics Inc., Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc., New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc., Cellectis S.A., Editas Medicine Inc.
The crispr and cas gene market report table of contents includes:
1. Executive Summary
2. CRISPR And Cas Gene Market Characteristics
3. CRISPR And Cas Gene Market Trends And Strategies
4. CRISPR And Cas Gene Market – Macro Economic Scenario
5. Global CRISPR And Cas Gene Market Size and Growth
.
.
.
27. Competitive Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Explore the trending research reports from TBRC:
https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report
https://www.thebusinessresearchcompany.com/report/dna-and-gene-chip-global-market-report
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-global-market-report
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
